Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Yuko OyaJeffrey S WeberKazuhiro AsadaTetsuya OguriNaoki InuiSayako MorikawaKentaro ItoTomoki KimuraEiji KuniiTakashi MatsuiAkihito KuboTatsuo KatoTakashi AbeTakeshi TsudaToyoaki HidaPublished in: BMC cancer (2021)
The detection of EGFR-driver and T790M in plasma by cobas in patients treated with afatinib might be lower than with G/E in a real-world setting.